Acquire, produce, process, and distribute therapeutic goods, primarily plasma-derived medicines. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $10.2B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 33.7× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
The stock trades 55% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 11% a year on average.
It pays out $0.05 per share each year — regular cash for whoever holds the stock.
The company’s market value is 34 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back.
Getting in and out without moving the price could prove difficult.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.